Lauren G. Gilstrap, MD, MPH

Articles by Lauren G. Gilstrap, MD, MPH

Coverage With Evidence Development: Where Are We Now?

ByEmily P. Zeitler, MD, MHS,Lauren G. Gilstrap, MD, MPH,Megan Coylewright, MD, MPH,David J. Slotwiner, MD,Carrie H. Colla, PhD,Sana M. Al-Khatib, MD, MHS

April 7th 2022

Review of CMS’ coverage with evidence development program exposes a need to improve program transparency and clarify requirements and timetables for reporting to improve access to novel therapies.

Latest Updated Articles

Coverage With Evidence Development: Where Are We Now?
Published: April 7th 2022 | Updated:

Lauren G. Gilstrap, MD, MPH

Articles by Lauren G. Gilstrap, MD, MPH

Coverage With Evidence Development: Where Are We Now?

Latest Updated Articles

Trending on AJMC

Trump Administration Flags Potential Link Between Prenatal Acetaminophen Use, Autism

Patient Cost, Convenience Important Considerations When Reviewing Formulary Approvals in Oncology: Q&A With Andrea Iannucci, PharmD, BCOP